Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?

Marker Therapeutics Inc MRKR released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter APOLLO clinical trial

The APOLLO trial is investigating the safety and efficacy of MT-601 for patients with lymphoma who have either failed or are ineligible to receive anti-CD19 CAR T cell therapy.

This first APOLLO study participant had diffuse large B cell lymphoma (DLBCL) and was enrolled into the Phase 1 dose escalation stage of the trial after failing four prior lines of therapy, including anti-CD19 CAR T cell therapy.

After relapse following anti-CD19 CAR T cell therapy, the participant was treated with two doses of MT-601 at the 200 million cell dose level without prior lymphodepletion. 

MT-601 treatment was well tolerated, with no reports of higher than Grade 1 treatment-related adverse events.

The tolerability at this initial dose level is consistent with the favorable clinical safety profile and tolerability previously reported for other multiTAA-specific T cell products. 

Eight weeks after the 2nd infusion of MT-601, the participant demonstrated a complete metabolic response based on PET-CT scans.

Marker previously reported non-clinical proof-of-concept data that showed that MT-601 could potentially eliminate lymphoma cells resistant to anti-CD19 CAR T cells, highlighting the therapeutic potential of MT-601 in vitro.

Price Action: MRKR shares are up 11.10% at $6.13 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!